Phase 2a safety and efficacy study results of obefazimod (ABX464) in patients with rheumatoid arthritis (RA) published in the renowned and peer-reviewed journal "Annals of the Rheumatic Diseases (ARD)"
Abivax Phase 2a Study Results of Obefazimod (ABX464) in Rheumatoid Arthritis Published in the Journal Annals of the Rheumatic Diseases and Selected for Presentation at EULAR 2022 theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.
Abivax SA , a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, today reports. | March 10, 2022
Abivax Reports Promising ABX464 Phase 2a One-Year Maintenance Results in Rheumatoid Arthritis newjerseytelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newjerseytelegraph.com Daily Mail and Mail on Sunday newspapers.